EUVIMEDEUVIMED entdecken
Crossref

1703-P: Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts

MARIA DERMIT, ALEJANDRO AGUAYO OROZCO, SARAH A.C. VOISIN, KASPER ADELBORG, DYLAN M. BELMONT-RAUSCH, HELEN M. COLHOUN, LUDGER J.E. GOEMINNE, VADIM GLADYSHEV, KRISTOFFER J. KOLNES, DONNA RYAN, LOTTE BJERRE KNUDSEN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1703-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MARIA DERMIT und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Semaglutide has shown benefits on multiple clinical endpoints, including reduction of all-cause mortality in adults with overweight/obesity and cardiovascular disease (CVD). We investigated the effect of semaglutide on biological age using mortality-based proteomics aging clocks developed in the UK BioBank, which reflect physiological deterioration.

Methods

We applied 2nd generation aging clocks to proteomics data from SELECT, STEP 1 and STEP 2 trials participants and assessed effect of semaglutide 2.4 mg treatment on multi-organ (combination of all organ-specific proteins) and organismal (combination of all non-organ-specific proteins) clocks.

Results

Semaglutide 2.4 mg reduced biological age assessed by multi-organ clocks, with similar effect sizes between cohorts (Figure), ie, 5.2% in SELECT (p<0.0001), 4.5% in STEP 1 (p<0.05), and 7.2% in STEP 2 (p<0.05). We found no effect of semaglutide on organismal biological age.

Conclusion

Semaglutide consistently reduced mortality-trained proteomic multi-organ biological age across patients with obesity and different comorbidities, while organismal clocks were unchanged. These findings suggest semaglutide modifies organ-specific proteomic signatures linked to mortality risk. Disclosure M. Dermit: None. A. Aguayo Orozco: Employee; Current; Novo Nordisk. S.A. Voisin: Employee; Current; Novo Nordisk A/S. K. Adelborg: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Novo Nordisk A/S. D.M. Belmont-Rausch: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Viking Therapeutics. Stock/Shareholder; Ended; Madrigal Pharmaceuticals, Inc. H.M. Colhoun: Research Support; Current; Diabetes UK, IQVIA Inc., Sanofi, JDRF, Chief Scientist Office. Research Support; Ended; Medical Research Council (UKRI). Other - Personal payment for consultancy (ENDED);Research support (ongoing); Current; Sanofi. Other - Advisory board member (ongoing); Support for attendance at meetings /conferences and travel; Current; Novo Nordisk. Other - Advisory panel member (ongoing);Stockholder (up to January 2025- ENDED); Current; Bayer AG. Other - Stockholder (ongoing);Institutional payment for consultancy (ongoing); Current; Roche Pharmaceuticals. L.J. Goeminne: None. V. Gladyshev: None. K.J. Kolnes: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. D. Ryan: Advisory Panel; Current; Abbvie, Altimmune, Amgen, AstraZenica, Boehringer Ingelheim, Biohaven, Carmot/Roche/Genentech. Advisory Panel; Ended; eMed, Fractyl, Nestle. Consultant; Current; Pfizer, Source Bio, Protagonist, PPD, Regeneron, Regor. Advisory Panel; Current; Currax, Structure Therapeutics, Tenvie, Kailera. Speaker's Bureau; Current; LIlly, Novo Nordisk,. Other - I am a consultant to both and received stock options and consulting fees.; Current; Calibrate, Epitomee. Other - Data Monitoring Committee member; Current; CinRx, Rhythm, Lilly. Advisory Panel; Current; Viking, Weight Watchers, Wonder Health, Zealand. Other - ! received non-negotiable stock options from these companies years ago and have not worked for them in years.; Ended; Roman, Scientific Intake. L. Bjerre Knudsen: Employee; Current; Novo Nordisk.

Zitieren

APA

DERMIT, M., OROZCO, A. A., VOISIN, S. A., ADELBORG, K., BELMONT-RAUSCH, D. M., COLHOUN, H. M., GOEMINNE, L. J., GLADYSHEV, V., KOLNES, K. J., RYAN, D., & KNUDSEN, L. B. (2026). 1703-P: Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1703-p

Vancouver

DERMIT M, OROZCO AA, VOISIN SA, ADELBORG K, BELMONT-RAUSCH DM, COLHOUN HM, et al. 1703-P: Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1703-p

BibTeX
@article{DERMIT2026,
  author = {DERMIT, MARIA and OROZCO, ALEJANDRO AGUAYO and VOISIN, SARAH A.C. and ADELBORG, KASPER and BELMONT-RAUSCH, DYLAN M. and COLHOUN, HELEN M. and GOEMINNE, LUDGER J.E. and GLADYSHEV, VADIM and KOLNES, KRISTOFFER J. and RYAN, DONNA and KNUDSEN, LOTTE BJERRE},
  title = {1703-P: Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1703-p}
}
Kostenlos starten →